Collin Shaw, Author at Buhlmann Diagnostics Corp

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® ELISA Calprotectin Test

BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 12, 2018: BÜHLMANN Laboratories AG, is proud to announce it has received United States Food and

IBDoc and Me

Health Canada Licence: 98903, Device class: 3 IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc® since last October and is trying this new tool to monitor his Crohn’s Disease. He has been documenting his experiences in a blog to share his

From BÜHLMANN Quantum Blue® to fCAL turbo® Follow the Evolution of Calprotectin Testing at James Cook University Hospital

Mr. Andrew Teggert, Clinical Scientist, James Cook University Hospital with SIEMENS ADVIA Chemistry XPT BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 An interview with Mr. Andrew Teggert, Clinical Scientist, James Cook University Hospital, Middlesbrough. At the largest hospital in Tees Valley,

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® IFX Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of IFX SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays. Journal of Crohns and Colitis. 2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US. Not for use in diagnostic procedures in the US. Health

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® IFX Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif. P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response. Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from

BUHLMANN LabSense News Winter 2018 Edition

BUHLMANN Diagnostics Corp is proud to release the sixth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. Check Out LabSense News Today! What's New Introducing BAT in Food Allergy Webinar recording and eBook by Dr. Alexandra Santos as well as two new IBDoc® Posters

Basophil Activation Test Identifies the Patients with Chronic Spontaneous Urticaria Suffering the Most Active Disease

Flow CAST® Assay: Curto-Barredo L, Yelamos et al. Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease. Immun Inflamm Dis. 2016 Oct 4;4(4):441-445. eCollection 2016 Dec. PubMed PMID: 27980778; doi: 10.1002/iid3.125. Highlights from this Publication “BAT was performed, measuring expression of the CD63 surface marker on basophils from whole blood by

The Advantages of an Immunoturbidimetric Assay for Measuring Calprotectin in Fecal Samples

Technical Details Speed An immunoturbidimetric assay (or particle-enhanced turbidimetric immunoassay (PETIA)) for measuring Calprotectin is the fastest solution in the market with the shortest time to first result regardless of using sample batches or random access. On average, the time to first result is 7.6 min [5 min -11.6 min] with additional results every 10.86

Calprotectin Assay Precision

BÜHLMANN fCAL® Assays BÜHLMANN fCAL® Assays have rock-solid performance that provide you with optimal precision to measure your results. Focus on what really matters - calprotectin results you can stand behind. Increase your efficiency and cost savings with BÜHLMANN fCAL® turbo, BÜHLMANN fCAL® ELISA, and Quantum Blue® fCAL. Precision & Linearity Data LEARN MORE Success Stories BÜHLMANN's calprotectin assays success stories

Assessment of Sensitization to Grape and Wine Allergens as Possible Causes of Adverse Reactions to Wine: A Pilot Study

Flow CAST® Assay: Jaeckels N, Bellinghausen I, Fronk P, Heydenreich B, Saloga J, Decker H. Assessment of sensitization to grape and wine allergens as possible causes of adverse reactions to wine: a pilot study. Clin Transl Allergy. 2015 Jun 22;5:21.PMID: 26101585 DOI: 10.1186/s13601-015-0065-8 Highlights from this Publication This article show the unique potential of BAT testing for studying specific allergies when

Author: Collin Shaw

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® ELISA Calprotectin Test

IBDoc and Me

From BÜHLMANN Quantum Blue® to fCAL turbo® Follow the Evolution of Calprotectin Testing at James Cook University Hospital

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BUHLMANN LabSense News Winter 2018 Edition

Basophil Activation Test Identifies the Patients with Chronic Spontaneous Urticaria Suffering the Most Active Disease

The Advantages of an Immunoturbidimetric Assay for Measuring Calprotectin in Fecal Samples

Calprotectin Assay Precision

Assessment of Sensitization to Grape and Wine Allergens as Possible Causes of Adverse Reactions to Wine: A Pilot Study

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US